Cidara Therapeutics Inc (CDTX NASDAQ) stock market data APIs
$216.526
1(0.5%)
as of November 17, 2025
Try our APIs with
free plan!
Cidara Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Prev. Close
216.526
Open
217.5233
High
217.4026
Low
217.5233
52 wk Range
14.93-218.85
Market Cap
6 845 M
Shares Outstanding
31 439 K
EPS
-3.1
Beta
1.553
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cidara Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cidara Therapeutics Inc data using free add-ons & libraries
Get Cidara Therapeutics Inc Fundamental Data
Cidara Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -159 776 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -1.3291
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cidara Therapeutics Inc News
New
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck MRK has made substantial investments in strategic mergers and acquisitions (M&A) deals over the past few years to build a more durable long-term portfolio and reinforce its growth prospects. La...
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 in...
Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout
Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion. JPMorgan cut its rating to Neutral...
Goldman Sachs on brink of best M&A performance in 24 years
Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant PREMIUM Upgrade to read this Financial Times article and get s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
